en · de · es · fr · pt
selank-notes.peptides9000.com › Topic › Selank Origin And Chemical Identity — Deep Dive

Selank Origin And Chemical Identity — Deep Dive

By Editorial Desk · published 2026-07-13 · last reviewed 2026-08-01 · Topic

Certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Selank Origin and Chemical Identity

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

Storage, Analysis, and Regulatory Status

Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.

Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideAnalog of the tetrapeptide tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProReported consistently across pharmacopoeial descriptions
AppearanceWhite to off-white lyophilized powderTypical form of research-grade material
SolubilityFreely soluble in waterAqueous buffers; poor in nonpolar solvents
Typical storage temperature-20 degrees CelsiusLyophilized powder; protect from moisture

Analytical Methods and Stability

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Related pages on this site

Selank Background And Chemical Identity

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Stability, Handling, and Analytical Control

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.

Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.

Notes from published material

=== Alcoholic drinks === In 2010, Starbucks began selling alcoholic beverages at some stores in the United States. In August 2014, Starbucks opened its first store in Williamsburg, Brooklyn which by then was among 30 locations serving beer and wine. In 2016, three locations within Toronto, Ontario also announced they were going to serve alcohol, including up-scale appetizers like bacon-wrapped dates and truffle mac and cheese. Starbucks ensures that the selected locations that serve alcohol are able to accommodate the community, as well as have the space for extra seating and storage.

== See also == Alfred Jost – first postulated the existence of a non-testesterone substance that suppressed Müllerian hormone Nathalie Josso – discovered and named AMH Anti-Müllerian hormone receptor Freemartin – involvement of anti-Müllerian hormone in cattle twins of mixed sex Persistent Müllerian duct syndrome (PMDS) Sexual differentiation

=== Vedolizumab === Vedolizumab is very similar to natalizumab in that it is a humanized IgG monoclonal antibody, but vedolizumab is an IgG1 that specifically blocks the alpha 4 beta 7 integrin that is located primarily on cells in the gastrointestinal tract. It is promoted as being gut specific due to the localization of alpha 4 beta 7 integrin in the gastrointestinal tract and was the first biologic to be made specifically for inflammatory bowel disease.

Sources: en.wikipedia.org

Further detail

=== In vitro studies === In vitro studies have shown that omadacycline has activity against a broad range of Gram-positive and select Gram-negative pathogens. Omadacycline has potent in vitro activity against Gram-positive aerobic bacteria including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant and multi-drug resistant Streptococcus pneumoniae, and vancomycin-resistant Enterococcus. Omadacycline also has antimicrobial activity against common Gram-negative aerobes, some anaerobes, and atypical bacteria such as Legionella and Chlamydia. This activity translated to potent efficacy for omadacycline in an in vivo systemic infection model in mice. Additional in vitro and in vivo studies of omadacycline metabolism, disposition, and drug interactions show that omadacycline is metabolically stable (i.e., it does not undergo significant biotransformation) and neither inhibits nor interacts with metabolizing enzymes or transporters.

These processes are increasingly aligned although important differences remain and drug developers must prepare separate documents. New development pathways have been developed to help with the approval of new antimicrobial agents that address unmet needs such as the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). These new pathways are required because of difficulties in conducting large definitive phase III clinical trials in a timely way. Some of the economic impediments to the development of new antimicrobial agents have been addressed by reimbursement schemes that delink payment of antimicrobials from volume-based sales. In the UK, a market entry reward scheme has been pioneered by the National Institute for Clinical Excellence (NICE) whereby an annual subscription fee is paid for use of strategically valuable antimicrobial agents – cefiderocol and ceftazidime-aviabactam are the first agents to be used in this manner and the scheme is potential blueprint for comparable programs in other countries. The available classes of antifungal drugs are still limited but as of 2021 novel classes of antifungals are being developed and are undergoing various stages of clinical trials to assess performance. Scientists have started using advanced computational approaches with supercomputers for the development of new antibiotic derivatives to deal with antimicrobial resistance.

==== Photodynamic cancer therapy ==== Various cancer treatments utilizing PDT have been approved by the FDA. Treatments are available for actinic keratosis (blue light with aminolevulinic acid), cutaneous T-cell lymphoma, Barrett esophagus, basal cell skin cancer, esophageal cancer, non-small cell lung cancer, and squamous cell skin cancer (Stage 0). Photosensitizing agents clinically-approved or undergoing clinical trials for the treatment of cancers include Photofrin, Temoporfin, Motexafin lutetium, Palladium bacteriopheophorbide, Purlytin, and Talaporfin. Verteporfin is approved to treat eye conditions such as macular degeneration, myopia, and ocular histoplasmosis. Third-generation photosensitizers are currently in development, but none are yet approved for clinical trials.

NP-40 (also known as Tergitol-type NP-40 and nonyl phenoxypolyethoxylethanol) is a commercially available detergent with CAS Registry Number 9016-45-9. NP-40 is an ethoxylated nonylphenol for non-ionic surfactants and can act as emulsifier and demulsifier agent. NP-40 is often used to break open all membranes within a cell, including the nuclear membrane . To break only the cytoplasmic membrane, other detergents such as digitonin can be used. NP-40 has applications in paper and textile processing, in paints and coatings, and in agrochemical manufacturing. Care should be taken to avoid confusing NP-40 with Nonidet P-40 (octyl phenoxypolyethoxylethanol) which is currently out of production. Nonidet P-40 ("Non-Ionic Detergent") was originally manufactured and trademarked by the Shell Chemical Company, but was phased out of production in the early 2000s. Confusingly, biochemical protocols published between the 1960s and 2000s refer to Shell's Nonidet P-40 as NP-40. Shell's original Nonidet P-40 had a hydrophilic-lipophilic balance (HLB) value of 13.5, as opposed to 12.9 for the currently available IGEPAL CA-630, indicating that the currently available compound is more potent than the compound used in older publications. Indeed, according to a 2017 report, an additional dilution factor of 10 was required for the currently available NP-40 ("Nonidet P-40 substitutes") to match the activity of the previously available, and now discontinued, Shell's Nonidet P-40.

Sources: en.wikipedia.org

Supporting material

By comparison, smaller scale civil defense programs were instituted in the United States starting in the 1950s, where schools and other public buildings had basements stocked with non-perishable food supplies, canned water, first aid, and dosimeter and Geiger counter radiation-measuring devices. Many of the locations were given "fallout shelter" designation signs. CONELRAD radio information systems were adopted, whereby the commercial radio sector (later supplemented by the National Emergency Alarm Repeaters) would broadcast on two AM radio frequencies in the event of a Civil Defense (CD) emergency. These two frequencies, 640 and 1240 kHz, were marked with small CD triangles on the tuning dial of radios of the period, as can still be seen on 1950s-vintage radios on online auction sites and museums. A few backyard fallout shelters were built by private individuals. Henry Kissinger's view on tactical nuclear war in his controversial 1957 book Nuclear Weapons and Foreign Policy was that any nuclear weapon exploded in air burst mode that was below 500 kilotons in yield and thus averting serious fallout, may be more decisive and less costly in human lives than a protracted conventional war. A list of targets made by the United States was released sometime during December 2015 by the U.S. National Archives and Records Administration. The language used to describe targets is "designated ground zeros".

=== Legal status === In September 2018, galcanezumab was approved in the United States for the preventive treatment of migraine in adults. The FDA granted the approval of Emgality to Eli Lilly. In November 2018, galcanezumab was approved for use in the European Union for the prophylaxis of migraine in adults who have at least four migraine days per month. In June 2019, galcanezumab was approved in the United States for the treatment of episodic cluster headache in adults. The application for galcanezumab was granted priority review and breakthrough therapy designations. In January 2021, AffaMed Therapeutics signed an agreement with Lilly to distribute galcenazumab in China. In December 2023, Organon signed an exclusive agreement with Lilly to distribute and commercialize galcanezumab in Europe. In August 2024, the agreement between Organon and Lilly was expanded to include a further 11 worldwide markets.

=== Pharmaceuticals === Over 30 nitrile-containing pharmaceuticals are currently marketed for a diverse variety of medicinal indications with more than 20 additional nitrile-containing leads in clinical development. The types of pharmaceuticals containing nitriles are diverse, from vildagliptin, an antidiabetic drug, to anastrozole, which is the gold standard in treating breast cancer. In many instances the nitrile mimics functionality present in substrates for enzymes, whereas in other cases the nitrile increases water solubility or decreases susceptibility to oxidative metabolism in the liver. The nitrile functional group is found in several drugs.

A study by the UC Davis Department of Viticulture and Enology found that recommendations on optimal nitrogen levels to complete a successful fermentation could be made based harvest brix level which have been adopted by many yeast and nutrient manufacturers.

Further problems arose with the West when in January 1989, two Libyan warplanes were shot down by the US off the Libyan coast and in September 1989, UTA Flight 772 was blown up over the Ténéré desert in Niger, killing all 170 people on board (156 passengers and 14 crew members). In 1996, Gaddafi wrote a letter to the newly elected Prime Minister of Bangladesh, Sheikh Mujibur Rahman's daughter Sheikh Hasina, pleading with her to spare the lives of her father's assassins Syed Faruque Rahman and Khandaker Abdur Rashid. Rahman and Rashid both had business ties to Libya. Many Arab and African states opposed the UN sanctions, with Mandela criticizing them on a visit to Gaddafi in October 1997, when he praised Libya for its work in fighting apartheid and awarded Gaddafi the Order of Good Hope. They would only be suspended in 1998 when Libya agreed to allow the extradition of the suspects to the Scottish Court in the Netherlands, in a process overseen by Mandela. As a result of the trial, Fhimah was acquitted and al-Megrahi convicted. Privately, Gaddafi maintained that he knew nothing about who perpetrated the bombing and that Libya had nothing to do with it.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.

How does it relate to tuftsin?

The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.

Is Selank an approved medicine?

It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.

How should the powder be stored?

Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.

Network